Summary
We examined the cardioprotective effect of nisoldipine against myocardial dysfunction during ischemia and reperfusion in Langendorff perfused rabbit hearts. Nisoldipine was administered to the hearts before 60 minutes of global ischemia. This agent inhibited the increase of end-diastolic pressure during ischemia and also improved the recovery of left ventricular developed pressure and coronary flow during reperfusion in a concentration-dependent manner. The maximal cardioprotective effect was observed in 10−8 M nisoldipine. The beneficial effect was associated with an increase of coronary flow during reperfusion. Therefore, both the nisoldipine-increased coronary flow during reperfusion and the inhibition of ischemic contracture by nisoldipine seem to play a crucial role in improving myocardial dysfunction of ischemic-reperfused hearts.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Kazda S, Garthoff B, Meyer H, et al. Pharmacology of a new calcium antagonist compound, isobutyl methyl 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl-3,5-pyridinedicarboxylate (Nisoldipine, Bay K5552).Arzneimittelforschung 1980;30:2144–2162.
Tzivoni D, Banai S, Botvin S, Zilberman A, Weiss TA, Gavish A. Effects of nisoldipine on myocardial ischemia during exercise and during daily activity.Am J Cardiol 1991;67:559–564.
Kimball BP, Watson KR, Bui S, Frankel D. Preservation of left ventricular performance with reduced ischemic dysfunction by intravenous nisoldipine.Am J Cardiol 1990;66:400–405.
Lahiri A, Rodrigues EA, Carboni GP, Raftery EB. Effects of long-term treatment with calcium antagonists on left ventricular diastolic function in stable angina and heart failure.Circulation 1990;81(Suppl 2):130–138.
Kern MJ. Influence of calcium channel antagonist therapy on the ischemic response to acute coronary occlusion in humans.Clin Cardiol 1989;12(Suppl 3):77–85.
Dunker DJ, van Woerkens LJ, Serruys PW, Roelandt JR, Hugenholtz PG, Verdouw PD. Actions of nisoldipine in cardiovascular disease.Can J Cardiol 1989;5:266–274.
Silke B, Frais MA, Midtbo KA, et al. Comparative hemodynamic dose-response effects of five slow calcium channel blocking agents in coronary artery disease.Clin Pharmacol Ther 1987;42:381–387.
Umeda M, Saida K. Improvement of ischemic myocardial dysfunction by nisoldipine in relation to its coronary vasodilating action.Jpn J Pharmacol 1993;62:1–7.
du Toit EF, Opie LH. Modulation of severity of reperfusion stunning in the isolated rat heart by agents altering calcium flux at onset of reperfusion.Circ Res 1992;70:960–967.
Watts JA, Hawes EM, Jenkins SH, Williams TC. Effects of nisoldipine on the no-reflow phenomenon in globally ischemic rat hearts.J Cardiovasc Pharmacol 1990;16:487–494.
de Jong JW. Timely administration of nisoldipine essential for prevention of myocardial ATP catabolism.Eur J Pharmacol 1985;118:53–59.
de Jong JW, Huizer T. Reduced glycolysis by nisoldipine treatment of ischemic heart.J Cardiovasc Pharmacol 1985;7:497–500.
Bergmeyer HU, Bernt E. UV-assay for lactate dehydrogenase with pyruvate and NADH. In: Bergmeyer HU, ed.Methods of Enzymatic Analysis, Vol. 2. Weinheim: Verlag Chemie GmbH, 1974:574–579.
Tumas J, Deth R, Kloner RA. Effects of nisoldipine, a new calcium antagonist, on myocardial intact size and cardiac dynamics following acute myocardial infarction.J Cardiovasc Pharmacol 1985;7:361–367.
Watts JA, Whipple JP, Hatley A. A low concentration of nisoldipine reduces ischemic heart injury: Enhanced reflow and recovery of contractile function without energy preservation during ischemia.J Mol Cell Cardiol 1987;19:809–817.
Tilton RG, Watts JA, Land MP, Larson KB, Sutera SP, Williamson JR. Discordant effects of nisoldipine on coronary vascular resistance and permeability changes during reflow after ischemia in isolated rabbit hearts.J Moll Cell Cardiol 1991;23:861–872.
Kihara Y, Grossman W, Morgan P. Direct measurement of changes in intracellular calcium transients during hypoxia ischemia, and reperfusion of the intact mammalian heart.Circ Res 1989;65:1029–1044.
Steenbergen C, Murphy E, Watts JA, London RE. Correlation between cystolic free calcium, contracture, ATP, and irreversible ischemic injury in perfused rat heart.Circ Res 1990;66:135–146.
Vandenberg JI, Metcalfe JC, Grace AA. Mechanisms of pHi recovery after global ischemia in the perfused heart.Circ Res 1993;72:993–1003.
Takayasu T, Toyo-oka T, Hosoda S. Waste of ATP for tension development in myocardial acidosis: Chemomechanical uncoupling at myofibrillar level.J Moll Cell Cardiol 1990;22:127–130.
Gavin JB, Humphrey SM, Herdson PB. The no-reflow phenomenon in ischemic myocardium.Int Rev Exp Pathol 1983;25:361–383.
Sassen LMA, Bezstarosti K, Verdouw PD, Lamers JMJ. Effects of nisoldipine on recovery of coronary blood flow, sarcoplasmic reticulum function and other biochemical parameters in post-ischemic porcine myocardium.Biochem Pharmacol 1991;41:43–51.
Grover GJ, Dzwonczyk S, Sleph PG. Comparative antiischemic effects of dihydropyridine calcium antagonists in isolated perfused rat hearts: Relationship of cardiodepression and cardioprotection.Pharmacology 1990;40:137–149.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Saida, K., Umeda, M. & Itakura, A. Improvement of ischemic myocardial dysfunction by nisoldipine. Cardiovasc Drug Ther 8 (Suppl 2), 365–370 (1994). https://doi.org/10.1007/BF00877321
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00877321